Rezolute, Inc. (RZLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
3.46 USD
-0.08
(-2.260%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.46 +0.00 (0.009%) ⇧ (April 17, 2026, 7:39 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:35 p.m. EDT
RZLT is a high-risk, high-reward stock with significant volatility. The recent price history shows a recovery from a sharp decline, but the fundamentals remain weak, with negative earnings and low revenue. The stock has a high short ratio and low liquidity, which could lead to increased price swings. While there are signs of potential short-term momentum, the long-term outlook is bleak due to the lack of consistent earnings and weak financials. The stock is not suitable for long-term investment but could be considered for short-term trading with a strong risk management strategy. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.122156 |
| AutoETS | 0.123910 |
| MSTL | 0.200015 |
| AutoTheta | 0.666671 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 63% |
| H-stat | 1.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.015 |
| Excess Kurtosis | 0.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.004 |
| Market Cap | 331,114,016 |
| Forward P/E | -5.06 |
| Beta | 0.66 |
| Website | https://www.rezolutebio.com |
As of April 11, 2026, 1:35 p.m. EDT: Options activity indicates mixed signals. Call options are concentrated around the $2.5 strike, suggesting some bullish sentiment, but there's heavy put activity on the $5.0 strike, indicating potential bearishness. The IV is generally low, suggesting limited volatility expectations. The presence of significant put options on higher strikes may signal caution or a potential for a price drop, while the call options suggest some optimism about a rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.10191083 |
| Address1 | 275 Shoreline Drive |
| Address2 | Suite 500 |
| All Time High | 750.0 |
| All Time Low | 0.72 |
| Ask | 3.5 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,456,920 |
| Average Daily Volume3 Month | 2,695,622 |
| Average Volume | 2,695,622 |
| Average Volume10Days | 1,456,920 |
| Beta | 0.659 |
| Bid | 3.41 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 1.234 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.46 |
| Current Ratio | 14.178 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.65 |
| Day Low | 3.45 |
| Debt To Equity | 1.004 |
| Display Name | Rezolute |
| Dividend Date | 1,602,547,200 |
| Earnings Timestamp | 1,770,930,000 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -88,381,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.257 |
| Enterprise Value | 199,460,992 |
| Eps Current Year | -0.7475 |
| Eps Forward | -0.68429 |
| Eps Trailing Twelve Months | -0.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.1794 |
| Fifty Day Average Change | 0.28060007 |
| Fifty Day Average Change Percent | 0.088255666 |
| Fifty Two Week Change Percent | 10.191083 |
| Fifty Two Week High | 11.457 |
| Fifty Two Week High Change | -7.9969997 |
| Fifty Two Week High Change Percent | -0.6980012 |
| Fifty Two Week Low | 1.07 |
| Fifty Two Week Low Change | 2.3899999 |
| Fifty Two Week Low Change Percent | 2.2336447 |
| Fifty Two Week Range | 1.07 - 11.457 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,358,173,800,000 |
| Float Shares | 65,462,958 |
| Forward Eps | -0.68429 |
| Forward P E | -5.056336 |
| Free Cashflow | -46,168,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10244001 |
| Held Percent Institutions | 0.95146006 |
| Implied Shares Outstanding | 95,697,685 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,602,547,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
| Long Name | Rezolute, Inc. |
| Market | us_market |
| Market Cap | 331,114,016 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_177932577 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -84,228,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 330,157,013 |
| Number Of Analyst Opinions | 8 |
| Open | 3.638 |
| Operating Cashflow | -77,149,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 206 4507 |
| Post Market Change | 0.00029993057 |
| Post Market Change Percent | 0.008668514 |
| Post Market Price | 3.4603 |
| Post Market Time | 1,776,469,178 |
| Previous Close | 3.54 |
| Price Eps Current Year | -4.6287627 |
| Price Hint | 4 |
| Price To Book | 2.80389 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.951 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -2.25989 |
| Regular Market Day High | 3.65 |
| Regular Market Day Low | 3.45 |
| Regular Market Day Range | 3.45 - 3.65 |
| Regular Market Open | 3.638 |
| Regular Market Previous Close | 3.54 |
| Regular Market Price | 3.46 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,108,200 |
| Return On Assets | -0.44092998 |
| Return On Equity | -0.74017996 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 95,697,685 |
| Shares Percent Shares Out | 0.13949999 |
| Shares Short | 13,353,457 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,858,606 |
| Short Name | Rezolute, Inc. |
| Short Percent Of Float | 0.21069999 |
| Short Ratio | 4.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | RZLT |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.125 |
| Target Median Price | 5.0 |
| Total Cash | 132,938,000 |
| Total Cash Per Share | 1.389 |
| Total Debt | 1,285,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.739675 |
| Two Hundred Day Average Change | -2.279675 |
| Two Hundred Day Average Change Percent | -0.3971784 |
| Type Disp | Equity |
| Volume | 1,108,200 |
| Website | https://www.rezolutebio.com |
| Zip | 94,065 |